Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

26 ArticlesFDA

3 / 3

Exclusive: Lupin Pharmaceuticals slapped form 483 for Goa facility

Welcome to the second of the 3 part exclusive unwrapping of the observations reported from the US FDA’s inspection of Lupin Pharmaceutical’s facilities. If ...
03-Lupin-fda-3-facilities-Goa.png

Exclusive: Lupin Pharmaceuticals slapped form 483 for Aurangabad facility

Welcome to the first of the 3 part exclusive unwrapping of the observations reported from the US FDA’s inspection of Lupin Pharmaceutical’s facilities. If ...
02-Lupin-fda-3-facilities-Aurangabad.png

Exclusive: Lupin Pharmaceuticals slapped form 483 for 3 facilities

Today we at Capital Mind bring you some exclusive articles. This follows our earlier post on Lupin’s Mandideep facility FDA inspection which was brought to ...
01-Lupin-fda-3-facilities.png

Anuh Pharma's Good Manufacturing Practices (GMP) certificate withdrawn

Anuh Pharma Limited (APL) – a BSE only listed stock, is part of Mumbai based SK group of companies is a mid-sized player in the API/bulk drug industry and is ...

Lupin’s tussle with the FDA and Investors – a lesson for the Pharma Industry

Lupin was and is all over the news. Why? Yesterday IIFL published an article in relation to the FDA’s inspection of Lupin’s Mandideep facility based on a ...
Lupin-Share-Price.png

Cadila Healthcare Gets Import Alert by WHO for Bad Manufacturing Practices

Cadila Healthcare was slapped with a World Health Organization (WHO) Notice of Concern (NOC) on the 29-Jan-15 (Note date: It’s three months ago) for the ...
Cadila-Healthcare-WHO-Letter.png